Your browser is no longer supported. Please, upgrade your browser.
LGND [NASD]
Ligand Pharmaceuticals Incorporated
Index- P/E- EPS (ttm)-0.21 Insider Own4.30% Shs Outstand16.08M Perf Week-1.67%
Market Cap2.39B Forward P/E30.09 EPS next Y4.86 Insider Trans-24.97% Shs Float15.28M Perf Month-6.20%
Income-3.00M PEG- EPS next Q1.12 Inst Own- Short Float17.95% Perf Quarter75.85%
Sales186.40M P/S12.80 EPS this Y432.60% Inst Trans-0.21% Short Ratio4.32 Perf Half Y36.26%
Book/sh43.39 P/B3.37 EPS next Y-21.17% ROA-1.90% Target Price224.67 Perf Year47.18%
Cash/sh48.75 P/C3.00 EPS next 5Y24.20% ROE-3.50% 52W Range57.24 - 219.75 Perf YTD47.15%
Dividend- P/FCF85.86 EPS past 5Y124.30% ROI45.50% 52W High-31.77% Beta1.16
Dividend %- Quick Ratio20.00 Sales past 5Y13.30% Gross Margin83.70% 52W Low161.93% ATR15.60
Employees115 Current Ratio20.30 Sales Q/Q68.50% Oper. Margin-2.40% RSI (14)46.91 Volatility6.42% 11.42%
OptionableYes Debt/Eq0.00 EPS Q/Q48.70% Profit Margin-13.20% Rel Volume0.76 Prev Close146.34
ShortableYes LT Debt/Eq0.65 EarningsFeb 03 BMO Payout- Avg Volume634.64K Price149.93
Recom2.20 SMA20-13.59% SMA509.82% SMA20034.99% Volume155,542 Change2.45%
Feb-04-21Reiterated H.C. Wainwright Buy $229 → $310
Oct-06-20Initiated Barclays Overweight $156
Mar-24-20Downgrade Argus Buy → Hold
Mar-10-20Initiated Guggenheim Neutral
Feb-06-20Initiated The Benchmark Company Buy $135
Sep-19-19Upgrade Barclays Equal Weight → Overweight $110 → $132
Jun-11-19Initiated Barclays Equal Weight $131
May-03-19Reiterated H.C. Wainwright Buy $254 → $214
Mar-06-19Reiterated H.C. Wainwright Buy $281 → $254
Oct-29-18Upgrade ROTH Capital Neutral → Buy
Oct-02-18Reiterated H.C. Wainwright Buy $270 → $280
Sep-11-18Reiterated Argus Buy $260 → $300
Aug-17-18Initiated Goldman Neutral $256
Aug-08-18Downgrade ROTH Capital Buy → Neutral
Jun-21-18Initiated Argus Buy $260
Dec-27-17Reiterated H.C. Wainwright Buy $163 → $169
Sep-05-17Resumed H.C. Wainwright Buy $150
Oct-05-16Reiterated H.C. Wainwright Buy $146 → $160
Aug-05-16Downgrade Deutsche Bank Hold → Sell $104 → $110
Mar-11-16Initiated Sidoti Buy
Feb-17-21 12:44PM  
Feb-11-21 01:40PM  
Feb-10-21 01:40PM  
Feb-09-21 06:40AM  
Feb-06-21 02:38AM  
Feb-05-21 04:39PM  
Feb-04-21 01:54PM  
08:56AM  
03:15AM  
Feb-03-21 01:30PM  
07:58AM  
07:30AM  
06:30AM  
Feb-02-21 11:59AM  
Feb-01-21 02:57PM  
Jan-28-21 08:04PM  
06:34PM  
Jan-27-21 01:06PM  
05:34AM  
Jan-20-21 12:45PM  
08:30AM  
Jan-19-21 04:18PM  
Jan-13-21 08:30AM  
Dec-23-20 10:15AM  
Dec-21-20 08:30AM  
Dec-18-20 02:43PM  
Dec-17-20 09:19AM  
Dec-06-20 03:59AM  
Nov-29-20 11:30AM  
Nov-23-20 08:30AM  
Nov-06-20 02:16PM  
Nov-02-20 11:06AM  
Oct-30-20 11:31PM  
09:25AM  
08:24AM  
08:00AM  
06:45AM  
Oct-28-20 12:00PM  
Oct-26-20 11:55PM  
Oct-23-20 12:30PM  
08:30AM  
Oct-22-20 04:42PM  
10:50AM  
Oct-20-20 02:05PM  
Oct-19-20 04:02PM  
Oct-06-20 09:25PM  
Oct-05-20 05:47PM  
Oct-02-20 08:00AM  
02:30AM  
Oct-01-20 08:24AM  
Sep-30-20 08:00AM  
Sep-25-20 11:40AM  
Sep-23-20 08:00AM  
Sep-18-20 07:16AM  
Sep-10-20 08:00AM  
Sep-09-20 11:40AM  
Sep-02-20 11:30AM  
Sep-01-20 04:02PM  
Aug-31-20 09:00AM  
Aug-25-20 04:15PM  
Aug-24-20 11:40AM  
08:30AM  
Aug-20-20 10:46AM  
Aug-12-20 10:32AM  
Aug-11-20 01:10PM  
08:20AM  
06:22AM  
Aug-10-20 05:36PM  
Aug-07-20 11:40AM  
08:30AM  
Aug-04-20 11:01AM  
Aug-03-20 02:10PM  
02:00PM  
08:55AM  
07:30AM  
Aug-02-20 11:08AM  
Jul-16-20 04:28PM  
Jul-13-20 07:51AM  
Jul-12-20 04:16PM  
Jul-08-20 10:00AM  
Jul-03-20 11:40AM  
Jun-29-20 12:48PM  
11:44AM  
09:12AM  
Jun-17-20 11:40AM  
Jun-15-20 08:30AM  
Jun-08-20 02:04PM  
Jun-05-20 11:31AM  
Jun-04-20 10:45PM  
Jun-03-20 06:43PM  
Jun-01-20 04:53PM  
11:40AM  
May-29-20 08:00AM  
May-28-20 04:22PM  
04:08PM  
May-22-20 08:58AM  
May-14-20 11:50AM  
May-07-20 04:00PM  
11:40AM  
11:11AM  
Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, focuses on developing and acquiring technologies that help pharmaceutical companies to discover and develop medicines worldwide. The company's commercial programs include Promacta, an oral medicine that increases the number of platelets in the blood; Kyprolis and Evomela, which are used to treat multiple myeloma; Baxdela, a captisol-enabled delafloxacin-IV for the treatment of acute bacterial skin and skin structure infections; Nexterone, a captisol-enabled formulation of amiodarone; Noxafil-IV, a captisol-enabled formulation of posaconazole for IV use; and Carnexiv, which is indicated as replacement therapy for oral carbamazepine formulations. It also offers bazedoxifene for the treatment of postmenopausal osteoporosis; Aziyo portfolio of commercial pericardial repair and CanGaroo envelope extracellular matrix products; Exemptia for autoimmune diseases; Vivitra for breast cancer; Minnebro for the treatment of hypertension; and Bryxta for non-small cell lung cancer. The company's partners programs, which are in clinical development used for the treatment of cancer, seizure, diabetes, cardiovascular disease, muscle wasting, liver disease, and kidney, and other diseases. It is also developing a small molecule glucagon receptor antagonist for the treatment of Type 2 diabetes mellitus. In addition, the company is involved in the sale of Captisol materials. Ligand Pharmaceuticals Incorporated was founded in 1987 and is headquartered in San Diego, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
KOZARICH JOHN WDirectorFeb 22Option Exercise10.122,50025,30029,708Feb 23 05:18 PM
Davis Todd CDirectorFeb 11Option Exercise195.912,474484,68150,152Feb 12 06:23 PM
Davis Todd CDirectorFeb 10Sale213.145,0831,083,41047,678Feb 12 06:23 PM
Sabba Stephen LDirectorFeb 09Option Exercise11.3314,670166,13839,101Feb 11 04:06 PM
Sabba Stephen LDirectorFeb 09Sale208.5314,6703,059,12324,431Feb 11 04:06 PM
HIGGINS JOHN LChief Executive OfficerFeb 05Option Exercise12.16114,6661,394,017346,030Feb 09 06:08 PM
HIGGINS JOHN LChief Executive OfficerFeb 05Sale203.4054,66611,119,239286,030Feb 09 06:08 PM
FOEHR MATTHEW WPresident and COOFeb 04Option Exercise23.0745,5471,050,890212,745Feb 05 05:03 PM
FOEHR MATTHEW WPresident and COOFeb 04Sale176.8644,5477,878,582168,198Feb 05 05:03 PM
Berkman Charles SSVP, Gen. Counsel & SecretaryFeb 04Sale178.5018,0973,230,37628,906Feb 05 05:03 PM
Davis Todd CDirectorJan 27Option Exercise113.502,456278,75652,761Jan 27 07:02 PM
HIGGINS JOHN LChief Executive OfficerJan 27Option Exercise17.6670,0001,236,400283,422Jan 27 07:04 PM
HIGGINS JOHN LChief Executive OfficerJan 27Sale182.0040,0007,280,000243,422Jan 27 07:04 PM
HIGGINS JOHN LChief Executive OfficerJan 25Option Exercise14.4750,000723,500285,310Jan 27 07:04 PM
HIGGINS JOHN LChief Executive OfficerJan 25Sale159.0050,0007,950,000235,310Jan 27 07:04 PM
HIGGINS JOHN LChief Executive OfficerDec 08Option Exercise10.0514,657147,303236,770Dec 09 06:12 PM
HIGGINS JOHN LChief Executive OfficerNov 09Option Exercise10.0520,000201,000224,571Nov 10 07:41 PM
Patel SunilDirectorNov 02Buy82.521,00082,52028,190Nov 04 04:19 PM
FOEHR MATTHEW WPresident and COOAug 24Option Exercise21.92781,710155,491Aug 25 07:10 PM
FOEHR MATTHEW WPresident and COOAug 24Sale110.89788,649155,413Aug 25 07:10 PM
FOEHR MATTHEW WPresident and COOAug 21Option Exercise20.388,015163,338162,638Aug 25 07:10 PM
FOEHR MATTHEW WPresident and COOAug 21Sale112.887,225815,541155,413Aug 25 07:10 PM
HIGGINS JOHN LChief Executive OfficerJul 07Option Exercise70.014,315302,098204,571Jul 09 04:28 PM
Berkman Charles SSVP, Gen. Counsel & SecretaryJun 04Sale118.5911,1461,321,77540,877Jun 05 04:07 PM
FOEHR MATTHEW WPresident and COOMar 13Option Exercise21.922,00043,840157,449Mar 13 06:33 PM
FOEHR MATTHEW WPresident and COOFeb 27Option Exercise15.898,931141,941160,968Feb 27 08:35 PM
FOEHR MATTHEW WPresident and COOFeb 27Sale110.007,225794,750153,743Feb 27 08:35 PM